Business
Assembly Biosciences Reports Year End 2024 Financial Results and Recent Highlights
– Four development candidates in clinical studies with data anticipated this year, continuing rapid progress of antiviral pipeline – – Interim Phase 1b proof-of-concept data, including initial efficacy measures, anticipated in fall 2025 for ABI-5366 and ABI-1179, long-acting helicase-primase inhibitor candidates for recurrent genital herpes – SOUTH SAN FRANCISCO, Calif., March 20, 2025 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative th
About this update from Assembly Biosciences, Inc.
[{"type":"image","alt":"Assembly Biosciences, Inc.","displaySize":"","headline":null,"caption":"Assembly Biosciences, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":62,"url":"https://media.zenfs.com/en/globenewswire.com/4e437adc40e964d1c4e7b4b8eba4cdc8"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/MDnne0t7yPjd24iiqZ4Sig--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTg3O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/4e437adc40e964d1c4e7b4b8eba4cdc8","width":300,"height":62}},"lazy":false},{"type":"text","content":"– Four development candidates in clinical studies with data anticipated this year, continuing rapid progress of antiviral pipeline –","length":132,"tagName":"p"},{"type":"text","content":"– Interim Phase 1b proof-of-concept data, including initial efficacy measures, anticipated in fall 2025 for ABI-5366 and ABI-1179, long-acting helicase-primase inhibitor candidates for recurrent genital herpes –","length":211,"tagName":"p"},{"type":"text","content":"SOUTH SAN FRANCISCO, Calif., March 20, 2025 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today reported financial results for the year ended December 31, 2024, and recent highlights.","length":293,"tagName":"p"},{"type":"text","content":"“We are well-positioned to deliver important clinical data on four of our novel antiviral candidates in 2025, including proof-of-concept efficacy data expected this fall from the Phase 1b studies of ABI-5366 and ABI-1179 for recurrent genital herpes,” said Jason Okazaki, chief executive officer and president of Assembly Bio. “We anticipate that the rapid progress across our clinical pipeline we saw in 2024 will continue this year, reinforcing the exceptional execution of our R&D organization and our commitment to changing the treatment paradigm for individuals living with serious viral diseases.”","length":607,"tagName":"p"},{"type":"text","content":"Fourth Quarter 2024 and Recent Highlights","length":41,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Recurrent genital herpes ","length":24,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Positive Phase 1a interim data released for ABI-1179","length":52,"tagName":"p"},{"type":"list","items":[{"val":[{"type":...